Drugs for Biliary Tract Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show top 50)
(show all 135)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Gemcitabine |
Approved |
Phase 3 |
|
95058-81-4, 122111-03-9 |
60750 |
Synonyms:
2',2'-DFDC
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-Amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
DDFC
DFDC
DFdCyd
Gemcin
GEMCITABIN
Gemcitabina
Gemcitabina [INN-Spanish]
GEMCITABINE
GEMCITABINE HCL
|
Gemcitabine hydrochloride
gemcitabine hydrochloride|Gemzar®
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
Gemtro
Gemzar
GEO
INFUGEM
LY188011
LY-188011
LY188011 HYDROCHLORIDE
LY-188011 HYDROCHLORIDE
NSC-613327
|
|
2 |
|
Capecitabine |
Approved, Investigational |
Phase 3 |
|
154361-50-9 |
60953 |
Synonyms:
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamate pentyl ester
(1-(5-Deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinyl)-carbamic acid pentyl ester
Capecitabin
Capecitabina
CAPECITABINE
Capécitabine
Capecitabinum
N(4)-Pentyloxycarbonyl-5'-deoxy-5-fluorocytidine
PENTYL [1-(3,4-DIHYDROXY-5-METHYL-OXOLAN-2-YL)-5-FLUORO-2-OXO-PYRIMIDIN-4-YL]AMINOFORMATE
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
|
Pentyl [1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamate
Pentyl [1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-2-oxo-1,2-dihydropyrimidin-4-yl]carbamic acid
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-b-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-beta-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamate
Pentyl 1-(5-deoxy-β-D-ribofuranosyl)-5-fluoro-1,2-dihydro-2-oxo-4-pyrimidinecarbamic acid
R340
RO-091978000
RO-09-1978000
RO-09-1978-000
Ro-09-1978-000|Ro-091978000|Xeloda®
Xeloda
|
|
3 |
|
Oxaliplatin |
Approved, Investigational |
Phase 3 |
|
61825-94-3 |
43805 11947679 6857599 |
Synonyms:
ACT 078
ACT-078
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatine
Elplat
Foloxatine
JM-83
L-OHP
L-OHP CPD
MBP-426 (LIPOSOMAL OXALIPLATIN)
NSC-266046
Oxalatoplatin
|
Oxalatoplatinum
Oxaliplatin
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
RP-54780
SR-96669
Transplatin
|
|
4 |
|
Magnesium sulfate |
Approved, Investigational, Vet_approved |
Phase 3 |
|
7487-88-9 |
|
Synonyms:
Magnesium sulfate (1:1)
Magnesium sulfate anhydrous
Magnesium sulphate
|
magnesium(II) sulfate
Magnesiumsulfat
MgSO4
|
|
5 |
|
Durvalumab |
Approved, Investigational |
Phase 3 |
|
1428935-60-7 |
|
Synonyms:
|
6 |
|
Cisplatin |
Approved |
Phase 3 |
|
15663-27-1 |
2767 5702198 441203 |
Synonyms:
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
Cis Pt II
cis-DDP
Cis-Diaminedichloroplatinum
Cis-Diamminedichloroplatinum
CIS-DIAMMINEDICHLOROPLATINUM(II)
Cismaplat
CISPLATIN
Cisplatine
cisplatino
CISPLATINUM
CIS-PLATINUM II
Cisplatyl
Citoplationo
CPDC
CPDD
DDP
DDPT
|
Diamminedichloroplatinum
INT230-6 COMPONENT CISPLATIN
INT-230-6 COMPONENT CISPLATIN
Lederplatin
Neoplatin
NSC-119875
Plastin
Platamine
Platiblastin
Platidiam
Platinex
PLATINOL
PLATINOL-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-Diaminedichloroplatinum
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
7 |
|
Trastuzumab |
Approved, Investigational |
Phase 3 |
|
180288-69-1 |
|
Synonyms:
4D5V8
ABP 980
ABP-980
ANTI HER2
D5v8|Herceptin®|R-597
DMB-3111 (TRASTUZUMAB BIOSIMILAR)
EG12014
EG-12014
HERCEPTIN
IG GAMMA-1 CHAIN C REGION
KADCYLA
|
R-597
RHUMAB HER2
SYD977
SYD-977
TRASTUZUMAB
TRASTUZUMAB BETA
trastuzumab-anns
trastuzumab-dkst
trastuzumab-dttb
trastuzumab-pkrb
trastuzumab-qyyp
|
|
8 |
|
Paclitaxel |
Approved, Vet_approved |
Phase 2, Phase 3 |
|
33069-62-4 |
36314 |
Synonyms:
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4b,4abeta,6b,9a(a r*,betas*),11a,12a,12balpha))-b-(benzoylamino)-a-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha r*,betas*),11alpha,12alpha,12balpha))-beta-(benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoate 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
(2AR-(2aalpha,4β,4abeta,6β,9α(α r*,betas*),11α,12α,12balpha))-β-(benzoylamino)-α-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5b,20-Epoxy-1,2-a,4,7b,10b,13a-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
5Β,20-epoxy-1,2-α,4,7β,10β,13α-hexahydroxytax-11-en-9-one 4,10-diacetic acid 2-benzoic acid 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine
7 Epi taxol
7-Epipaclitaxel
7-Epi-paclitaxel
7-epipaclitaxel|Abraxane® (albumin-bound suspension)|Taxol®
7-Epitaxol
7-Epi-taxol
ABI-007
ABRAXANE
Anzatax
BMS 181339-01
BMS-181339-01
Bris taxol
CAPXOL
CYCLOPAX
DHP 107
|
EBETAXEL
Epitaxol
GENETAXYL
GENEXOL
INTAXEL
LIPOPAC
MBT 0206
MITOTAX
NK 105
NSC-125973
Onxol
PACITAXEL
PACLITAXEL
Paclitaxel, (4 alpha)-isomer
Paxceed
Paxene
PLAXICEL
Praxel
QW-8184
TAXALBIN
TAXOL
TAXOL 100
Taxol a
Taxol, bris
Vascular Wrap
Xorane
YEWTAXAN
|
|
9 |
|
Niraparib |
Approved, Investigational |
Phase 3 |
|
1038915-60-4 |
24958200 |
Synonyms:
COMPOUND 56 [PMID 19873981]
compound 56 [PMID 19873981]|MK 4827|MK-4827|Zejula®
JNJ-64091742
MK 4827
|
MK4827
MK-4827
NIRAPARIB
ZL-2306
|
|
10 |
|
Futibatinib |
Approved, Investigational |
Phase 3 |
|
1448169-71-8 |
71621331 |
Synonyms:
1-((3S)-(4-amino-3-((3,5-dimethoxyphenyl)ethynyl)-1H-pyrazolo(3, 4-d) pyrimidin-1-yl)-1-pyrrolidinyl)-2-propen-1-one
1-[(3S)-3-{4-amino-3-[(3,5-dimethoxyphenyl)ethynyl]-1H-pyrazolo[3,4-d]pyrimidin-1-yl}pyrrolidin-1-yl]prop-2-en-1-one
Example 2 [WO2013108809]|FGFR-IN-1|Lytgobi®|TAS 120|TAS-120|TAS120
|
FUTIBATINIB
TAS 120
TAS-120
|
|
11 |
|
Ivosidenib |
Approved, Investigational |
Phase 3 |
|
1448347-49-6 |
78140854 71657455 |
Synonyms:
AG-120
AG-120|AG120|Tibsovo®
IVOSIDENIB
|
N-((1S)-1-(2-Chlorophenyl)-2-((3,3-difluorocyclobutyl)amino)-2-oxoethyl)-1-(4-cyano-2-pyridinyl)-N-(5-fluoro-3-pyridinyl)-5-oxo-L-prolinamide
TIBSOVO
|
|
12 |
|
Levoleucovorin |
Approved, Experimental, Investigational |
Phase 3 |
|
68538-85-2, 58-05-9, 73951-54-9 |
149436 6006 |
Synonyms:
(5-formyl-5,6,7,8-tetrahydropteroyl)glutamate
(6R)-Leucovorin
(6R,2'S)-Folinic acid
(6R,S)-5-Formyltetrahydrofolate
(6S)-5-Formyl-5,6,7,8-tetrahydrofolate
(6S)-5-FORMYL-5,6,7,8-TETRAHYDROFOLIC ACID
(6S)-5-Formyltetrahydrofolate
(6S)-5-FORMYLTETRAHYDROFOLIC ACID
(6S)-Folinate
(6S)-FOLINIC ACID
(6S)-LEUCOVORIN
(S)-LEUCOVORIN
[6R]-5-formyl-5,6,7,8-tetrahydrofolate
10-Formyl-7,8-dihydrofolate
10-Formyl-7,8-dihydrofolic acid
5 Formyltetrahydrofolate
5 Formyltetrahydropteroylglutamate
5-Formlyl-5,6,7,8-tetrahydrofolate,calcium salt
5-Formyl-(6S)-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydrofolate
5-Formyl-5,6,7,8-tetrahydrofolic acid
5-Formyl-5,6,7,8-tetrahydropteroyl-L-glutamic acid
5-Formyltetrahydrofolate
5-Formyltetrahydrofolic acid
5-Formyltetrahydropteroylglutamate
5-Formyltetrahydropteroylglutamic acid
5-formylTHF
6 S Leucovorin
6R-Leucovorin
6S Leucovorin
6S-Leucovorin
6-S-Leucovorin
Acid, folinic
Acide folinique
Acido folinico
ácido levofolínico
Calcium citrovorum factor
Calcium folinate
Calcium leucovorin
CF
Citrovorum factor
Dextrofolinic acid
Factor, citrovorum
Folinate
Folinate, calcium
Folinic acid
Folinic acid calcium salt
Folinic acid calcium salt USP27
Folinic acid SF
Folinic acid-SF
FUSILEV
KHAPZORY
|
Kunyrin
L(-)-5-Formyl-5,6,7,8-tetrahydrofolate
L(-)-5-Formyl-5,6,7,8-tetrahydrofolic acid
Leucal
Leucoverin
Leucovorin
Leucovorin calcium
Leucovorin folinic acid
Leucovorin, (D)-isomer
Leucovorin, (DL)-isomer
Leucovorin, (R)-isomer
Leucovorin, (S)-isomer
Leucovorin, calcium
Leucovorin, calcium (1:1) salt
Leucovorin, calcium (1:1) salt, (DL)-isomer
Leucovorin, calcium (1:1) salt, (S)-isomer
Leucovorin, calcium (1:1) salt, pentahydrate
Leucovorin, monopotassium salt, (S)-isomer
Leucovorin, monosodium salt
Leucovorin, monosodium salt, (S)-isomer
Leucovorinum
Leukovorin
Leukovorum
Levo leucovorin
LEVOFOLENE
Levofolinate
LEVOFOLINIC ACID
Levoleucovorin
Levo-leucovorin
L-Folinate
L-FOLINIC ACID
LFP-754
L-Leucovorin
L-N-[P-[[(2-amino-5-Formyl-5,6,7,8-tetrahydro-4-hydroxy-6-pteridinyl)methyl]amino]benzoyl]-glutamic acid
Monosodium salt leucovorin
N(5)-Formyltetrahydrofolate
N-(5-formyl-5,6,7,8-tetrahydropteroyl)-L-glutamic acid
N-[4-({[(6S)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)benzoyl]-L-glutamate
N-[4-({[(6S)-2-AMINO-5-FORMYL-4-OXO-1,4,5,6,7,8-HEXAHYDROPTERIDIN-6-YL]METHYL}AMINO)BENZOYL]-L-GLUTAMIC ACID
N-{[4-({[(6R)-2-amino-5-formyl-4-oxo-1,4,5,6,7,8-hexahydropteridin-6-yl]methyl}amino)phenyl]carbonyl}-L-glutamic acid
N5-Formyl-5,6,7,8-tetrahydrofolate
N5-Formyl-5,6,7,8-tetrahydrofolic acid
N5-Formyltetrahydrofolate
N5-Formyltetrahydrofolic acid
N5-Formyl-THF
Pteroyl-D-glutamate
Rescuvolin
S Leucovorin
S-Leucovorin
Welcovorin
Wellcovorin
|
|
13 |
|
Fluorouracil |
Approved |
Phase 3 |
|
51-21-8 |
3385 |
Synonyms:
5 Fluorouracil
5 Fluorouracil biosyn
5 FU
5 FU lederle
5 FU medac
5 HU hexal
5.F.U.
5-Fluoracil
5-Fluoropyrimidine-2,4-dione
5-Fluorouracil
5-Fluorouracil-biosyn
5-Fluracil
5FU
5-FU
5-FU lederle
5-FU medac
5-HU hexal
ACCUSITE
ACTIKERALL
Adrucil
Allergan brand OF fluorouracil
Arumel
Biosyn brand OF fluorouracil
Carac
Carzonal
CSP Brand OF fluorouracil
Dakota brand OF fluorouracil
Dakota, fluorouracile
Dermatech brand OF fluorouracil
Dermik brand OF fluorouracil
Effluderm
Efudex
Efudix
Efurix
Ferrer brand OF fluorouracil
Fluoro Uracil
Fluoro uracile icn
Fluoroblastin
Fluoroplex
Fluorouracil
Fluorouracil gry
Fluorouracil mononitrate
Fluorouracil monopotassium salt
Fluorouracil monosodium salt
Fluorouracil potassium salt
FLUORO-URACIL ROCHE
Fluorouracil teva brand
|
Fluorouracile dakota
Fluoro-uracile icn
Fluorouracil-gry
Fluorouracilo
Fluorouracilo ferrer far
Fluorouracilum
Fluoruracil
Fluouracil
Fluracedyl
FLURACIL
Fluracilum
Fluri
Fluril
Fluro Uracil
Flurodex
Flurouracil
Ftoruracil
FU
Gry brand OF fluorouracil
Haemato brand OF fluorouracil
Haemato fu
Haemato-fu
Hexal brand OF fluorouracil
ICN brand OF fluorouracil
Kecimeton
Medac brand OF fluorouracil
Neocorp brand OF fluorouracil
Neofluor
NSC-19893
Onkofluor
Onkoworks brand OF fluorouracil
Pharmachemie brand OF fluorouracil monosodium salt
Phthoruracil
Phtoruracil
Queroplex
Ribofluor
Ribosepharm brand OF fluorouracil
Riemser brand OF fluorouracil
RO-29757
RO-2-9757
Roche brand OF fluorouracil
Teva brand OF fluorouracil
Timazin
TOLAK
Ulup
URF
|
|
14 |
|
Folic acid |
Approved, Nutraceutical, Vet_approved |
Phase 3 |
|
59-30-3 |
6037 |
Synonyms:
(2S)-2-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)FORMAMIDO]PENTANEDIOIC ACID
(2S)-2-[[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]-OXO-METHYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]GLUTARIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]BENZOYL]AMINO]PENTANEDIOIC ACID
(2S)-2-[[4-[(2-AMINO-4-OXO-1H-PTERIDIN-6-YL)METHYLAMINO]PHENYL]CARBONYLAMINO]PENTANEDIOIC ACID
[<sup>3</sup>H]-folic acid
Acide folique
ácido fólico
Acidum folicum
ACIFOLIC
Apo-Folic
B03BB01
b9, Vitamin
BIO SCIENCE
CYTOFOL
DOSFOLAT B ACTIV
FOLACID
FOLACIN
FOLATE
FOLBAL
FOLCIDIN
FOLDINE
FOLETTES
FOLIAMIN
FOLIC ACID
Folic acid, (D)-isomer
Folic acid, (DL)-isomer
Folic acid, calcium salt (1:1)
Folic acid, monopotassium salt
Folic acid, monosodium salt
Folic acid, potassium salt
Folic acid, sodium salt
FOLICARE
FOLICET
FOLIPAC
|
FOLSAEURE
FOLSAN
FOLSAURE
Folsäure
FOLSAV
FOLVITE
Folvron
INCAFOLIC
LEXPEC
LIVER LACTOBACILLUS CASEI FACTOR
MILLAFOL
N-(4-{[(2-AMINO-4-OXO-3,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}BENZOYL)-L-GLUTAMIC ACID
N-[(4-{[(2-amino-4-oxo-1,4-dihydropteridin-6-yl)methyl]amino}phenyl)carbonyl]-L-glutamate
N-[(4-{[(2-AMINO-4-OXO-1,4-DIHYDROPTERIDIN-6-YL)METHYL]AMINO}PHENYL)CARBONYL]-L-GLUTAMIC ACID
N-[4-[[(2-AMINO-3,4-DIHYDRO-4-OXO-6-PTERIDINYL)METHYL]AMINO]BENZOYL]-L-GLUTAMIC ACID
NATUR FLOW
N-Pteroyl-L-glutamate
N-PTEROYL-L-GLUTAMIC ACID
NSC-3073
PGA
PRECONCEIVE
PTEGLU
PTEROYLGLUTAMATE
PTEROYLGLUTAMIC ACID
PTEROYL-L-GLUTAMATE
PTEROYL-L-GLUTAMIC ACID
PTEROYL-L-MONOGLUTAMATE
PTEROYL-L-MONOGLUTAMIC ACID
PTEROYLMONOGLUTAMIC ACID
ROCHE
Vitamin B9
VITAMIN BC
VITAMIN BE
VITAMIN M
|
|
15 |
|
Cediranib |
Investigational |
Phase 2, Phase 3 |
|
288383-20-0 |
9933475 |
Synonyms:
4-((4-Fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxy-7-(3-(pyrrolidin-1-yl)propoxy)quinazoline
4-(4-FLUORO-2-METHYLINDOL-5-YLOXY)-6-METHOXY-7-[3-(PYRROLIDIN-1-YL)PROPOXY]QUINAZOLINE
AZD 2171
AZD 2171|AZD2171|ZD 2171
AZD-2171
|
CEDIRANIB
RECENTIN
ZD 2171
ZD-2171
|
|
16 |
|
Antiemetics |
|
Phase 3 |
|
|
|
17 |
|
Emetics |
|
Phase 3 |
|
|
|
18 |
|
Antiviral Agents |
|
Phase 3 |
|
|
|
19 |
|
Anti-Infective Agents |
|
Phase 3 |
|
|
|
20 |
|
Mitogens |
|
Phase 2, Phase 3 |
|
|
|
21 |
|
Antineoplastic Agents, Immunological |
|
Phase 3 |
|
|
|
22 |
|
Albumin-Bound Paclitaxel |
|
Phase 2, Phase 3 |
|
|
|
23 |
|
Poly(ADP-ribose) Polymerase Inhibitors |
|
Phase 3 |
|
|
|
24 |
|
Antimetabolites |
|
Phase 3 |
|
|
|
25 |
|
Immunosuppressive Agents |
|
Phase 3 |
|
|
|
26 |
|
Immunologic Factors |
|
Phase 3 |
|
|
|
27 |
|
Vitamins |
|
Phase 3 |
|
|
|
28 |
|
Folate |
|
Phase 3 |
|
|
|
29 |
|
Vitamin B9 |
|
Phase 3 |
|
|
|
30 |
|
Trace Elements |
|
Phase 3 |
|
|
|
31 |
|
Vitamin B Complex |
|
Phase 3 |
|
|
|
32 |
|
Antidotes |
|
Phase 3 |
|
|
|
33 |
|
Micronutrients |
|
Phase 3 |
|
|
|
34 |
|
Protective Agents |
|
Phase 3 |
|
|
|
35 |
|
Racepinephrine |
Approved, Vet_approved |
Phase 2 |
|
51-43-4, 329-65-7 |
838 5816 |
Synonyms:
(−)-(R)-epinephrine
(-)-(R)-Epinephrine
(-)-3,4-Dihydroxy-a-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-a-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-Dihydroxy-a-[2-(methylamino)ethyl]benzyl alcohol
(-)-3,4-Dihydroxy-alpha-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-alpha-[(methylamino)methyl]-benzyl alcohol
(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]BENZYL ALCOHOL(-)-3,4-DIHYDROXY-ALPHA-[(METHYLAMINO)METHYL]-BENZYL ALCOHOL
(-)-3,4-Dihydroxy-alpha-[2-(methylamino)ethyl]benzyl alcohol
(−)-3,4-dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-3,4-Dihydroxy-α-((methylamino)methyl)benzyl alcohol
(-)-Adrenaline
(−)-ADRENALINE
(-)-Epinephrine
(+-)-Adrenaline
(+-)-Epinephrine
(R)-(-)-Adnephrine
(R)-(-)-Adrenaline
(R)-(−)-ADRENALINE
(R)-(-)-Epinephrine
(R)-(-)-Epirenamine
(R)-4-[1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
(R)-Adrenaline
(R)-Epinephrine
2-(Methylamino)-1-(3,4-dihydroxyphenyl)ethanol
4-(1-Hydroxy-2-(methylamino)ethyl)-1,2-benzenediol
4-[(1R)-1-Hydroxy-2-(methylamino)ethyl]-1,2-benzenediol
4-[(1R)-1-HYDROXY-2-METHYLAMINOETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]BENZENE-1,2-DIOL
4-[(1R)-1-HYDROXY-2-METHYLAMINO-ETHYL]PYROCATECHOL
Acetate, epinephrine
Adnephrine
ADREN CO
ADRENACLICK
Adrenal
Adrenalin
adrenalin|Auvi-Q®|Epipen®|l-adrenaline|L-epinephrine|levoepinephrine
Adrenaline
Adrénaline
Adrenaline acid tartrate
Adrenaline bitartrate
Adrenaline hydrochloride
Adrenaline hydrochloride, racemic mixture
Adrenaline, racemic
Adrenaline, racemic mixture
adrenaline|epinephrine
Adrenine
Adrin
Allergan brand OF adrenaline hydrochloride
ANA-GUARD
Ana-kit
ANAPEN
ANAPHYLACTIC SHOCK DRUG KIT
ASMA-VYDRIN
ASTHMAHALER
Auvi-Q
Bird brand OF racepinefrine hydrochloride
Bosmin
Bronkaid mist
BROVON
Chelafrin
DL-Adrenaline
EMERADE
EPI E Z PEN JR
Epifrin
Epiglaufrin
Epinefrin
Epinefrina
Epinephran
Epinephrin
EPINEPHRINE
Epinephrine acetate
Epinephrine bitartrate
EPINEPHRINE HCL
Epinephrine hydrochloride
Epinephrine hydrochloride, racemic mixture
Epinephrine hydrogen tartrate
Epinephrine racemic
Epinephrine, racemic
Epinephrine, racemic mixture
Epinephrinum
Epipen
|
EPIPEN E Z PEN
Epipen JR
EPIPEN JR.
Epirenan
Epitrate
Eppy
Exadrin
Glauposine
GPPE INH SOLN
Hemisine
Hemostasin
Hemostatin
Hydrochloride, racepinephrine
Hypernephrin
Isoptoepinal
JEXT
L-1-(3,4-Dihydroxyphenyl)-2-methylaminoethanol
L-Adrenaline
L-DETHYLAMINOETHANOLCATECHOL
L-Epinephrine
L-Epirenamine
Levoepinephrine
LEVO-METHYLAMINOETHANOLCATECHOL
Levorenen
Levorenin
Levorenine
Levoreninum
L-Methylaminoethanolcatechol
Lyodrin
Lyophrin
Medihaler-epi
Methylarterenol
Micronefrin
Micronephrine
Mixture adrenaline, racemic
Mixture epinephrine, racemic
Mucidrina
Nephridine
Nieraline
NSC-62786
Paranephrin
Primatene
Primatene mist
R-(-)-Epinephrine
Racemic adrenaline
Racemic epinephrine
Racemic mixture adrenaline
Racemic mixture epinephrine
Racepinefrina
Racepinefrine
Racepinefrinum
Racepinephrine
Racepinephrine hydrochloride
Renaglandin
Renaleptine
Renalina
Renoform
Renostypticin
Renostyptin
RIDDOBRON
RIDDOFAN
RYBARVIN
Scurenaline
Simplene
SOLN MADE TO RYBARVIN FOR
Styptirenal
Supracapsulin
Supranephrane
Suprarenaline
Suprarenin
Surrenine
Sus-phrine
SUS-PHRINE SULFITE FREE
SUS-PHRINE SULFITE-FREE
SYMJEPI
Takamina
TWINJECT
TWINJECT 0.15
TWINJECT 0.3
Vaponefrin
Vasoconstrictine
Vasotonin
|
|
36 |
|
Ropivacaine |
Approved |
Phase 2 |
|
84057-95-4 |
71273 175805 |
Synonyms:
(-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
(-)-1-Propyl-2',6'-pipecoloxylidide
(+-)-Ropivacaine
(S)-(-)-1-Propyl-2',6'-pipecoloxylidide
(S)-(−)-1-PROPYL-2',6'-PIPECOLOXYLIDIDE
(S)-ROPIVACAINE
1 Propyl 2',6' pipecoloxylidide
1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilide
1-Propyl-2',6'-pipecoloxylidide
1-propyl-2',6'-pipecoloxylidide|AL-381|LEA-103|Naropin®|ropivacaine hydrochloride
AL-381
DL-Ropivacaine
LEA 103
LEA-103
L-N-N-Propylpipecolate-2,6-xylidide
L-N-N-Propylpipecolic acid-2,6-xylidide
Naropeine
|
Naropin
N-N-Propylpipecolate-2,6-xylidide
N-N-Propylpipecolic acid-2,6-xylidide
Racemic ropivacaine
rac-Ropivacaine
Ropivacaina
Ropivacaina [INN-Spanish]
Ropivacaina [Spanish]
Ropivacaine
Ropivacaine [INN]
Ropivacaine hydrochloride
Ropivacaine monohydrochloride
Ropivacaine monohydrochloride, (S)-isomer
Ropivacainum
Ropivacainum [INN-Latin]
S-Ropivacaine
|
|
37 |
|
Fentanyl |
Approved, Illicit, Investigational, Vet_approved |
Phase 2 |
|
437-38-7 |
3345 |
Synonyms:
1-Phenethyl-4-(N-phenylpropionamido)piperidine
1-Phenethyl-4-N-propionylanilinopiperidine
ABSTRAL
Abstral®|Actiq®|Durogesic®|Effentora®|MCN-JR-4263-49|R-4263|Sublimaze®
ACTIQ
AD 923
AD-923
BREAKYL
Cephalon brand OF fentanyl buccal oravescent
Duragesic
DURAGESIC-100
DURAGESIC-12
DURAGESIC-25
DURAGESIC-37
DURAGESIC-50
DURAGESIC-75
Durogesic
DUROGESIC DTRANS
EFFENTORA
FENCINO
FENTALIS RESERVOIR
Fentanest
Fentanil
Fentanila
Fentanila [INN-Spanish]
Fentanilo
Fentanyl
Fentanyl CII
Fentanyl citrate
FENTANYL-100
FENTANYL-12
FENTANYL-25
FENTANYL-37
FENTANYL-50
FENTANYL-62
FENTANYL-75
FENTANYL-87
Fentanylum
|
Fentanylum [INN-Latin]
Fentora
IDS-NF-001
INNOVAR
IONSYS
Janssen pharmaceutica brand OF fentanyl
LEPTANAL
MATRIFEN
MCN-JR-4263-49
MEZOLAR MATRIX
MYLAFENT
N-(1-Phenethyl-4-piperidinyl)-N-phenylpropionamide
N-(1-Phenethyl-4-piperidyl)propionanilide
N-(1-Phenethylpiperidin-4-yl)-N-phenylpropionamide
N-(1-Phenethyl-piperidin-4-yl)-N-phenyl-propionamide
N02AB03
Nasalfent
N-Phenethyl-4-(N-propionylanilino)piperidine
N-Phenyl-N-(1-(2-phenylethyl)-4-piperidinyl)propanamide
OPIODUR
ORALET
OSMACH
OSMANIL
PECFENT
Pentanyl
Phentanyl
R 4263
R-4263
Rapinyl
RECIVIT
Sentonil
Sublimaze
Subsys
TILOFYL
Transmucosal oral fentanyl citrate
VICTANYL
YEMEX
|
|
38 |
|
Oxycodone |
Approved, Illicit, Investigational |
Phase 2 |
|
76-42-6 |
5284603 |
Synonyms:
(-)-14-Hydroxydihydrocodeinone
4,5a-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5alpha-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5-Epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
4,5Α-epoxy-14-hydroxy-3-methoxy-17-methylmorphinan-6-one
Combunox
Dihydro-14-hydroxycodeinone
Dihydrohydroxycodeinone
Dihydrohydroxycondeinone
Dihydrone
Dihydroxycodeinone
Dinarkon
Diphydrone
Endocet
Endodan
Endone
Eubine
Eucodal
Eucodalum
Eukodal
Eutagen
IDS-NO-002
N02AA05
NSC-19043
Oxanest
Oxicodona
Oxicodona [INN-Spanish]
Oxicon
OXICONE
Oxiconum
Oxikon
Oxycodeinon
|
Oxycodeinone
Oxycodon
OXYCODONE
OXYCODONE CII
Oxycodone Hcl
Oxycodone hydrochloride
Oxycodonum
Oxycodonum [INN-Latin]
Oxycon
Oxycone
Oxycontin
OxyFAST
OxyIR
OxyNorm
Pancodine
Percobarb
Percodan
Percolone
PF-00345439
PROLADONE
PTI-821
Purdue frederick brand OF oxycodone
Remoxy
ROXICODONE
Supendol
Supeudol
Tecodin
Tekodin
Thecodine
Thekodin
Theocodin
XTAMPZA ER
|
|
39 |
|
Morphine |
Approved, Investigational |
Phase 2 |
|
57-27-2 |
5288826 |
Synonyms:
(-)-Heroin hydrochloride
(-)-Morphine
(−)-MORPHINE
(5a,6a)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5a,6a)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5alpha,6alpha)-17-Methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5alpha,6alpha)-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(5R,6S,9R,13S,14R)-4,5-Epoxy-N-methyl-7-morphinen-3,6-diol
(5Α,6α)-17-methyl-7,8-didehydro-4,5-epoxymorphinan-3,6-diol
(5Α,6α)-didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol
(7R,7AS,12BS)-3-methyl-2,3,4,4a,7,7a-hexahydro-1H-4,12-methano[1]benzofuro[3,2-e]isoquinoline-7,9-diol
ANHYDROUS MORPHINE
Apokyn
Astramorph PF
AVINZA
Chloride, morphine
Contin, MS
D-(-)-Morphine
DEPODUR
Diacetylmorphine hydrochloride
Diamorphine hydrochloride
Dulcontin
Duramorph
Duramorph PF
Duromorph
Epimorph
Heroin hydrochloride
Heroine hydrochloride
IDS-NM-009
INFUMORPH
KADIAN
l-Morphine
M.O.S
Meconium
M-Eslon
Morfina
Morfina dosa
|
Morphia
Morphin
Morphina
MORPHINE
Morphine chloride
Morphine Extra-Forte
Morphine Forte
Morphine H.P
Morphine sulfate
Morphine sulfate (2:1), anhydrous
Morphine sulfate (2:1), pentahydrate
morphine sulfate|Ms Contin®|Oramorph®
Morphinism
Morphinum
Morphitec
Morphium
Moscontin
MS Contin
MS/L
MS/S
MSIR
N02AA01
Nepenthe
O,O'-Diacetylmorphine hydrochloride
OMS Concentrate
ORAMORPH
Oramorph SR
Ospalivina
Rescudose
RMS Uniserts
Roxanol
Roxanol 100
Roxanol UD
Statex
Statex Drops
Substitol
Sulfate, morphine
|
|
40 |
|
Cetuximab |
Approved |
Phase 2 |
|
205923-56-4 |
|
Synonyms:
ABP-494
ANTI EGFR
C225
C-225
C225|Erbitux®|IMC-225|IMC-C225
CETUXIMAB
Cétuximab
CETUXIMAB (GENETICAL RECOMBINATION)
|
Cetuximabum
CMAB009
CMAB-009
ERBITUX
IMC-225
IMC-C225
MOAB C225
|
|
41 |
|
Mitomycin |
Approved |
Phase 2 |
|
50-07-7 |
5746 |
Synonyms:
7-Amino-9alpha-methoxymitosane
7-Amino-9a-methoxymitosane
7-Amino-9α-methoxymitosane
Ametycine
Mitamycin
Mitocin C
MitocinC
Mitocin-C
Mitomycin
|
Mitomycin C
Mitomycin-C
MITOSOL
MITOZYTREX
MMC
Muamycin
Mutamycin
MYTOZYTREX
NSC-26980
|
|
42 |
|
Panitumumab |
Approved, Investigational |
Phase 2 |
|
339177-26-3 |
|
Synonyms:
ABX-EGF
ABX-EGF|ABX-EGF Mab|Vectibix®
E7.6.3
|
L01XC08
PANITUMUMAB
VECTIBIX
|
|
43 |
|
Sargramostim |
Approved, Investigational |
Phase 2 |
|
123774-72-1 |
|
Synonyms:
B1 61.012
B1-61012
LEUKINE
RECOMBINANT GM-CSF
Recombinant human granulocyte-macrophage colony stimulating factor
|
rGM-CSF
RHU GM-CSF
RHU-GM-CSF
SARGRAMOSTIM
|
|
44 |
|
Olaparib |
Approved |
Phase 2 |
|
763113-22-0 |
23725625 |
Synonyms:
1-(CYCLOPROPYLCARBONYL)-4-[5-[(3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL]-2-FLUOROBENZOYL]PIPERAZINE
4-(3-{[4-(CYCLOPROPYLCARBONYL)PIPERAZIN-1-YL]CARBONYL}-4-FLUOROBENZYL)PHTHALAZIN-1(2H)-ONE
AZ2281
AZ-2281
AZD2281
AZD-2281
AZD-2281|AZD2281|Lynparza®
|
KEYLYNK-010 COMPONENT OLAPARIB
KU-0059436
KU59436
KU-59436
Lynparza
OLAPARIB
OLAPARIB COMPONENT OF KEYLYNK-010
|
|
45 |
|
Erlotinib |
Approved, Investigational |
Phase 2 |
|
183319-69-9, 183321-74-6 |
176870 |
Synonyms:
[6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine
[6,7-Bis(2-methoxy-ethoxy)quinazoline-4-yl]-(3-ethynylphenyl)amine
11C Erlotinib
11C-Erlotinib
CP-358
CP-358,774
CP-358774
CP-35877401
CP-358774-01
ERLOTINIB
Erlotinib HCL
Erlotinib hydrochloride
Erlotinibum
|
HCL, Erlotinib
Hydrochloride, erlotinib
N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine
NSC 718781
NSC 718781|OSI 744|OSI-774|R 1415|Tarceva®
OSI 744
OSI 774
OSI-774
R 1415
R-1415
RG-1415
RO-508231
Tarceva
|
|
46 |
|
Adenosine |
Approved, Investigational |
Phase 2 |
|
58-61-7 |
60961 |
Synonyms:
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-(HYDROXYMETHYL)TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4R,5R)-2-(6-AMINOPURIN-9-YL)-5-METHYLOL-TETRAHYDROFURAN-3,4-DIOL
(2R,3R,4S,5R)-2-(6-AMINO-9H-PURIN-9-YL)-5-(HYDROXYMETHYL)OXOLANE-3,4-DIOL
(2R,3R,4S,5R)-2-(6-Aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-delta-ribofuranose
1-(6-Amino-9H-purin-9-yl)-1-deoxy-beta-D-ribofuranose
6-Amino-9-b-D-ribofuranosyl-9H-purine
6-Amino-9beta-delta-ribofuranosyl-9H-purine
6-Amino-9beta-D-ribofuranosyl-9H-purine
6-Amino-9-beta-D-ribofuranosyl-9H-purine
6-Amino-9-β-D-ribofuranosyl-9H-purine
9-b-D-Ribofuranosidoadenine
9-b-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Arabinofuranosyladenine
9-beta-delta-Arabinofuranosyladenine
9-beta-delta-Ribofuranosidoadenine
9beta-delta-Ribofuranosyl-9H-purin-6-amine
9-beta-delta-Ribofuranosyl-9H-purin-6-amine
9beta-delta-Ribofuranosyladenine
9-beta-delta-Ribofuranosyladenine
9-beta-D-Ribofuranosidoadenine
9beta-D-Ribofuranosyl-9H-purin-6-amine
9-beta-D-Ribofuranosyl-9H-purin-6-amine
9beta-D-Ribofuranosyladenine
9-beta-D-Ribofuranosyladenine
9-Î’-D-ribofuranosidoadenine
9-Î’-D-ribofuranosyl-9H-purin-6-amine
ADENIN RIBOSIDE
Adenine deoxyribonucleoside
|
Adenine nucleoside
Adenine riboside
Adenine-9beta-delta-ribofuranoside
Adenine-9beta-D-ribofuranoside
Adenocard
Adenocard®|Adenoscan®
Adenocor
ADENOGESIC
Adenoscan
Adenosin
ADENOSINA
ADENOSINE
ADÉNOSINE
ADENOSINUM
Adenyldeoxyriboside
Ade-rib
Ado
b-D-Adenosine
beta-Adenosine
beta-D-Adenosine
beta-delta-Adenosine
Boniton
Deoxyadenosine
Desoxyadenosine
Myocol
NSC-7652
Nucleocardyl
Sandesin
SR-96225
Î’-D-adenosine
|
|
47 |
|
Fludarabine |
Approved |
Phase 2 |
|
75607-67-9, 21679-14-1 |
30751 657237 |
Synonyms:
2-F-ARAA
2-F-Ara-A|CCRIS 3382|F-Ara-A|Fludara®
2F-Ara-AMP
2-fluoro ARA-A
2-Fluoroadenine arabinoside 5'-monophosphate
2-Fluoroadenine arabinoside 5'-monophosphoric acid
2-Fluoro-ara AMP
2-FLUORO-ARA-A
9 beta-D-Arabinofuranosyl-2-fluoroadenine monophosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-b-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-b-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-beta-Arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-beta-D-Arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphate
9-Î’-arabinofuranosyl-2-fluoroadenine-5'-phosphoric acid
|
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphate)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-(dihydrogen phosphoric acid)
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphate
9-Î’-D-arabinofuranosyl-2-fluoroadenine 5'-monophosphoric acid
Beneflur
FAMP
FaraAMP
F-Ara-AMP
Fludara
Fludarabina
FLUDARABINE
Fludarabine 5'-monophosphate
Fludarabine 5'-monophosphoric acid
Fludarabine monophosphate
Fludarabine monophosphoric acid
Fludarabine phosphate
Fludarabine phosphoric acid
Fludarabinum
Fludura
Fluoro-ara-AMP
NSC-312887
NSC-328002
OFORTA
|
|
48 |
|
Aldesleukin |
Approved |
Phase 2 |
|
110942-02-4 |
|
Synonyms:
125-L-serine-2-133-interleukin 2 (human reduced)
Aldesleukin
Aldesleukina
IL-2
ILT101
ILT-101
Interleukin-2 aldesleukin
|
INTERLEUKIN-2 PRECURSOR
Interleukin-2(2-133),125-ser
Recombinant human interleukin-2
Recombinant interleukin-2 human
T-CELL GROWTH FACTOR
TCGF
|
|
49 |
|
Cyclophosphamide |
Approved, Investigational |
Phase 2 |
|
50-18-0, 6055-19-2 |
2907 |
Synonyms:
(+-)-Cyclophosphamide
(+,-)-2-(Bis(2-chloroethyl)amino)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide monohydrate
(RS)-Cyclophosphamide
2-[Bis(2-chloroethylamino)]-tetrahydro-2H-1,3,2-oxazaphosphorine-2-oxide
Anhydrous cyclophosphamide
Anhydrous, cyclophosphamide
ASTA
Asta B 518
Bis(2-chloroethyl)phosphoramide cyclic propanolamide ester
Ciclofosfamida
Ciclofosfamide
Clafen
Claphene
CP
CPA
CTX
CY
Cyclophosphamid
Cyclophosphamide
Cyclophosphamide anhydrous
Cyclophosphamide monohydrate
Cyclophosphamide Sterile
Cyclophosphamide, (R)-isomer
Cyclophosphamide, (S)-isomer
Cyclophosphamidum
Cyclophosphan
Cyclophosphane
Cyclophosphoramide
|
Cyclostin
Cyklofosfamid
Cytophosphan
Cytophosphane
Cytoxan
Cytoxan Lyoph
Endoxan
Endoxan R
Endoxana
Endoxanal
Endoxan-Asta
Endoxane
Enduxan
Genoxal
Hexadrin
LEDOXINA
Lyophilized Cytoxan
Mitoxan
Monohydrate, cyclophosphamide
N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide
Neosar
Procytox
Rcra Waste Number U058
Revimmune
Semdoxan
Sendoxan
Senduxan
Zyklophosphamid
|
|
50 |
|
Pemetrexed |
Approved, Investigational |
Phase 2 |
|
150399-23-8, 137281-23-3 |
60843 446556 135565230 |
Synonyms:
(2R)-2-{[4-(2-{4-hydroxy-2-imino-1H,2H,7H-pyrrolo[2,3-D]pyrimidin-5-yl}ethyl)phenyl]formamido}pentanedioate
ALIMTA
Alimta®|LY-231514
Disodium, pemetrexed
LY-2315
LY231514
|
LY-231514
MTA
N-(4-(2-(2-Amino-3,4-dihydro-4-oxo-7H-pyrrolo(2,3-D)pyrimdin-5-yl)ethyl)benzoyl)glutamic acid
NSC-698037
Pemetrexed
Pemetrexed disodium
|
|
Interventional clinical trials:
(show top 50)
(show all 297)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
The Effect of Individualized Precision Therapy Programs in Patients With Biliary Tract Cancer |
Unknown status |
NCT02943031 |
Phase 4 |
|
2 |
RCT Steel (Wallstent®) vs Nitinol (Wallflex®) Bile Duct Stent for Palliation of Malignant Obstruction |
Completed |
NCT00980889 |
Phase 4 |
|
3 |
Re-intervention for Occluded Biliary Metal Stent in Malignant Distal Bile Duct Obstruction: a Prospective Randomized Multi-center Trial Comparing Covered and Uncovered Metal Stent |
Completed |
NCT01315522 |
Phase 4 |
|
4 |
Endoscopic Radiofrequency Ablation for Malignant Biliary Obstruction |
Completed |
NCT01758341 |
Phase 4 |
|
5 |
A Randomized, Open, Multi-center Phase IIb/III Clinical Study to Assess the Efficacy and Safety of Surufatinib Compared to Capecitabine in Advanced or Metastatic Biliary Tract Carcinoma (BTC) Patients |
Unknown status |
NCT03873532 |
Phase 2, Phase 3 |
Surufatinib;Capecitabine |
6 |
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy |
Completed |
NCT03093870 |
Phase 2, Phase 3 |
Varlitinib;Capecitabine;Placebo (for Varlitinib) |
7 |
A Randomised Clinical Trial Evaluating Adjuvant Chemotherapy With Capecitabine Compared to Expectant Treatment Alone (Observation) Following Surgery for Biliary Tract Cancer |
Completed |
NCT00363584 |
Phase 3 |
capecitabine |
8 |
Randomized Phase III Trial Comparing Gemcitabine/Cisplatin/S-1 With Gemcitabine/Cisplatin for Unresectable Biliary Tract Cancer |
Completed |
NCT02182778 |
Phase 3 |
Gemcitabine/Cisplatin;Gemcitabine/Cisplatin /S-1 |
9 |
A Phase III, Randomised, Multicentre Open-label Study of Active Symptom Control (ASC) Alone or ASC With Oxaliplatin/ 5F-U Chemotherapy for Patients With Locally Advanced/ Metastatic Biliary Tract Cancers Previously Treated With Cisplatin/ Gemcitabine Chemotherapy. |
Completed |
NCT01926236 |
Phase 3 |
L-folinic acid;5 FU;Oxaliplatin |
10 |
Evaluation of Effects of Early Palliative Care on Quality of Life of Advanced Cancer Patients. A Multicenter Controlled Randomised Clinical Trial |
Completed |
NCT02988635 |
Phase 3 |
|
11 |
Randomised Phase II Trial of Cediranib (AZD2171) Versus Placebo in Addition to Cisplatin/Gemcitabine Chemotherapy for Patients With Advanced Biliary Tract Cancers |
Completed |
NCT00939848 |
Phase 2, Phase 3 |
gemcitabine;cisplatin;Placebo;cediranib |
12 |
A Prospective Randomized Clinical Trial of Two Surgical Techniques for Pancreaticojejunostomy in Patients Undergoing Pancreaticoduodenectomy: Nonstented Stump-closed vs Duct-to-Mucosa Pancreaticojejunostomy |
Completed |
NCT01731821 |
Phase 3 |
|
13 |
Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine for Biliary Tract Cancer After Curative Resection |
Recruiting |
NCT03779035 |
Phase 3 |
Gemcitabine;Capecitabine |
14 |
A Randomized, Multi-center Phase III Trial of Adjuvant Chemotherapy With Gemcitabine and Capecitabine Compared to Capecitabine Alone in Curatively Resected Biliary Tract Cancer |
Recruiting |
NCT04401709 |
Phase 3 |
Gemcitabine/Capecitabine;Capecitabine |
15 |
Gemcitabine and Oxaliplatin With or Without KN035 for Biliary Tract Cancer: a Randomised, Open-label, Parallel-group, Multicenter Phase III Study |
Recruiting |
NCT03478488 |
Phase 3 |
KN035 plus Gemcitabine & oxaliplatin;Gemcitabine & oxaliplatin |
16 |
Randomized, Placebo-controlled, Open-label, Phase 2b Clinical Trial to Evaluate the Antitumor Activity of Combination Therapy of SMT-NK and Pembrolizumab vs Pembrolizumab Monotherapy in Patients With Advanced Biliary Tract Cancer |
Recruiting |
NCT05429697 |
Phase 2, Phase 3 |
SMT-NK inj.+Pembrolizumab;Pembrolizumab |
17 |
Neoadjuvant Chemotherapy With Gemcitabine Plus Cisplatin Followed by Radical Liver Resection Versus Immediate Radical Liver Resection Alone With or Without Adjuvant Chemotherapy in Incidentally Detected Gallbladder Carcinoma After Simple Cholecystectomy or in Front of Radical Resection of BTC (ICC/ECC) - A Phase III Study of the German Registry of Incidental Gallbladder Carcinoma Platform (GR) - The AIO/ CALGP/ ACO- GAIN-Trial - |
Recruiting |
NCT03673072 |
Phase 3 |
Gemcitabine;Cisplatin;Adjuvant chemotherapy |
18 |
A Randomized, Open-label, Parallel Controlled, Multi-center Phase III Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule Versus Chemotherapy as Second-line Treatment in Subjects With Advanced Biliary Cancer |
Recruiting |
NCT04809142 |
Phase 3 |
TQB2450 Injection;Anlotinib hydrochloride;Oxaliplatin injection;Capecitabine tablets;Gemcitabine hydrochloride injection |
19 |
A Phase II/III, Multicenter, Randomized, Placebo-controlled Study of Gemcitabine Plus Cisplatin With or Without Bintrafusp Alfa (M7824) as First-line Treatment of Biliary Tract Cancer |
Active, not recruiting |
NCT04066491 |
Phase 2, Phase 3 |
M7824;Placebo;Gemcitabine;Cisplatin |
20 |
A Phase III Randomized, Double-Blind Placebo Controlled, Multi-Regional, International Study of Durvalumab in Combination With Gemcitabine Plus Cisplatin Versus Placebo in Combination With Gemcitabine Plus Cisplatin for Patients With First-Line Advanced Biliary Tract Cancers |
Active, not recruiting |
NCT03875235 |
Phase 3 |
Durvalumab;Placebo |
21 |
A Phase III Randomized Trial of Gemcitabine, Cisplatin, and Nab-Paclitaxel Versus Gemcitabine and Cisplatin in Newly Diagnosed, Advanced Biliary Tract Cancers |
Active, not recruiting |
NCT03768414 |
Phase 3 |
Cisplatin;Gemcitabine Hydrochloride;Nab-paclitaxel |
22 |
Open-Label, Multicenter, Phase II/III Study of Combination Therapy of D07001-Softgel Capsules and Xeloda/TS-1 in Subjects With Advanced Biliary Tract Cancer After Gemcitabine and Cisplatin-Based Treatment Failure |
Not yet recruiting |
NCT05065957 |
Phase 2, Phase 3 |
D07001-softgel capsules + Xeloda (or TS-1);mFOLFOX |
23 |
An Open, Single-arm Prospective Clinical Study Evaluating the Efficacy of Systemic Venous Gemcitabine-based Chemotherapy Combined With Immunocheckpoint Inhibitors in First-line Treatment of Advanced Biliary Malignancies |
Not yet recruiting |
NCT05487443 |
Phase 2, Phase 3 |
Gemcitabine-based chemotherapy regimen combined with immunocheckpoint inhibitors |
24 |
A Phase 2/3 Randomized, Controlled Study of CTX-009 in Combination With Paclitaxel Versus Paclitaxel Alone in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Who Have Received One Prior Systemic Chemotherapy Regimen |
Not yet recruiting |
NCT05506943 |
Phase 2, Phase 3 |
CTX-009;Paclitaxel |
25 |
Molecular Targeted Maintenance Therapy Versus Standard of Care in Advanced Biliary Cancer: an International, Randomised, Controlled, Open-label, Platform Phase 3 Trial |
Not yet recruiting |
NCT05615818 |
Phase 3 |
Futibatinib;Ivosidenib;Zanidatamab;Trastuzumab;Neratinib;Encorafenib;Binimetinib;Niraparib;Cisplatin;Gemcitabine |
26 |
A Phase III Open-Label, Multi-Centre, Randomized Study Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Previously Untreated Locally Advanced or Metastatic Biliary Tract Cancer |
Terminated |
NCT04163900 |
Phase 3 |
NUC-1031;Gemcitabine;Cisplatin |
27 |
A Phase 3 Multicenter, Open Label, Randomized Study of XL119 Versus 5-Fluorouracil (5-FU) Plus Leucovorin (LV) in Subjects With Advanced Biliary Tumors Not Amenable to Conventional Surgery |
Terminated |
NCT00090025 |
Phase 3 |
becatecarin;5-Fluorouracil Plus Leucovorin |
28 |
A Randomized, Open-Label, Comparative, Parallel-Group, Multicenter Study of SPARC1507 in Subjects With Cancer |
Withdrawn |
NCT02597465 |
Phase 3 |
SPARC1507;Reference1507 |
29 |
GAMBIT Trial: A Randomized,Non-comparative, Open-label Clinical Trial Evaluating Cisplatin Plus Irinotecan in the Treatment of Gallbladder or Biliary Tract Cancer |
Unknown status |
NCT01859728 |
Phase 2 |
Irinotecan;Cisplatin;Gemcitabine |
30 |
An Exploratory Study to Evaluate Efficacy and Safety of Fruquintinib as Second-line Treatment for Patients With Advanced or Metastatic Biliary Tract Cancer |
Unknown status |
NCT04156958 |
Phase 2 |
Fruquintinib |
31 |
A Multicentre, Open-label Phase II Study of Nab-paclitaxel in Combination With Gemcitabine + Cisplatin as First Line Treatment in Patients With Unresectable Biliary Tract Cancer |
Unknown status |
NCT02632305 |
Phase 2 |
nab-paclitaxel in combination with gemcitabine + cisplatin |
32 |
Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin Compared With Gemcitabine +Cisplatin as First-line Chemotherapy for Unresectable or Metastatic Biliary Tract Cancer: A Randomized, Controlled, Multicenter Phase II Clinical Trial |
Unknown status |
NCT04300959 |
Phase 2 |
Anlotinib Hydrochloride in Combination With PD1 With Gemcitabine Plus(+)Cisplatin;Gemcitabine Plus(+)Cisplatin |
33 |
A Phase II Study for Nab-paclitaxel Plus Cisplatin vs Gemcitabine Plus Cispatin as First Line Chemotherapy in Advanced Biliary Tract Cancer |
Unknown status |
NCT04692051 |
Phase 2 |
Nab-paclitaxel + Cisplatin;Gemcitabine + Cisplatin |
34 |
Phase II Study of Apatinib as Second Line Therapy in Patients With Advanced Refractory Biliary Tract Cancer |
Unknown status |
NCT03144856 |
Phase 2 |
Apatinib |
35 |
A Phase I/II, Open-label, Single-center Study to Evaluate the Safety and Efficacy of the Pan-immunotherapy in Subjects With Local Advanced/Metastatic Biliary Tract Cancer |
Unknown status |
NCT04004234 |
Phase 1, Phase 2 |
Manganese Chloride;nab-paclitaxel;Gemcitabine;anti-PD-1 antibody |
36 |
Phase II Study of S-1 in Combination With Oxaliplatin and Irinotecan in Patients With Advanced, Recurrent or Metastatic Biliary Tract Cancer |
Unknown status |
NCT02527824 |
Phase 2 |
Oxaliplatin, Irinotecan, S-1 |
37 |
Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center, Phase II Clinical Study |
Unknown status |
NCT04027764 |
Phase 2 |
Toripalimab Combined With S1 and Albumin Paclitaxel |
38 |
Phase II Randomized Trial of S-1, Leucovorin, Oxaliplatin and Gemcitabine (SLOG) vs Gemcitabine and Cisplatin (GC) in Locally Advanced or Metastatic Biliary Tract Cancer |
Unknown status |
NCT03406299 |
Phase 2 |
Tegafur;Leucovorin;Oxaliplatin;Gemcitabine;Cisplatin |
39 |
A Multicenter, Phase I-II Trial of Gemcitabine Plus Oxaliplatin and Nab-paclitaxel in Subjects With Advanced (Unresectable or Metastatic) Biliary Tract Cancer |
Unknown status |
NCT03943043 |
Phase 1, Phase 2 |
nab-paclitaxel |
40 |
Multicenter Phase II Study of Docetaxel and Oxaliplatin Combination in Patients With Locally Advanced or Metastatic Biliary Tract Cancer |
Unknown status |
NCT01234051 |
Phase 2 |
Docetaxel, Oxaliplatin |
41 |
An Pilot Study of S-1 Combined With Oxaliplatin for First-line Treatment of Unresectable, Metastatic or Locally Advanced Biliary Tract Cancer or Ampullary Adenocarcinoma |
Unknown status |
NCT01180153 |
Phase 2 |
S-1 oxaliplatin |
42 |
Multicenter Phase II Study of Fluorouracil, Leucovorin, Oxaliplatin, and Irinotecan (FOLFOXIRI) in Patients With Locally Advanced or Metastatic Biliary Tract Cancer |
Unknown status |
NCT01494363 |
Phase 2 |
Fluorouracil;Leucovorin;Oxaliplatin;Irinotecan |
43 |
A Pilot Study of PD-1 Inhibitor in Combination With Gemcitabine/Cisplatin for Patients With Advanced Unresectable or Metastatic Biliary Tract Cancers |
Unknown status |
NCT03311789 |
Phase 1, Phase 2 |
PD-1 inhibitor + Gemcitabine + Cisplatin |
44 |
Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study |
Unknown status |
NCT04211168 |
Phase 2 |
Toripalimab plus Lenvatinib |
45 |
A Phase 2 Study of Pyrotinib in Patients With Advanced/ Metastatic HER2-Altered Biliary Tract Cancers Who Have Failed One or Two Prior Lines of Therapies |
Unknown status |
NCT04571710 |
Phase 2 |
SHR1258 |
46 |
Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System |
Unknown status |
NCT03185988 |
Phase 2 |
chemotherapy in combination with trastuzumab for arm1;chemotherapy in combination with trastuzumab for arm2;chemotherapy in combination with trastuzumab for arm3;chemotherapy in combination with trastuzumab for arm4 |
47 |
Phase II Study of Second Line Capecitabine Plus Oxaliplatin (XELOX) in Patients With Advanced Biliary Tract Carcinoma After Failure of Gemcitabine-based Chemotherapy |
Unknown status |
NCT02350686 |
Phase 2 |
capecitabine;oxaliplatin |
48 |
Phase II Exploratory Study of S-1 Combined With Oxaliplatin Sequential S-1 Single-agent First-line Treatment of Unresectable Metastatic or Locally Advanced Biliary System, Periampullary Cancer and Pancreatic Cancer |
Unknown status |
NCT01811277 |
Phase 2 |
SOX sequential S-1 |
49 |
A Multicenter Phase II Trial of Preoperative Chemotherapy With Gemcitabine/ Cisplatin /S-1 (GCS) for Biliary Tract Cancers With Lymph Node Metastasis Diagnosed by Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) |
Unknown status |
NCT01821248 |
Phase 2 |
Gemcitabine, Cisplatin, S-1 |
50 |
Comparison of Analgesic Efficacy After Major Surgery in Pancreatobiliary Cancers: Intravenous Patient-controlled Analgesia Versus Patient-controlled Epidural Analgesia |
Unknown status |
NCT04352023 |
Phase 2 |
|
|